JP2019507761A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019507761A5 JP2019507761A5 JP2018545432A JP2018545432A JP2019507761A5 JP 2019507761 A5 JP2019507761 A5 JP 2019507761A5 JP 2018545432 A JP2018545432 A JP 2018545432A JP 2018545432 A JP2018545432 A JP 2018545432A JP 2019507761 A5 JP2019507761 A5 JP 2019507761A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- oncolytic virus
- combination
- virus
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 48
- 244000309459 oncolytic virus Species 0.000 claims description 34
- 206010028980 Neoplasm Diseases 0.000 claims description 32
- 239000002955 immunomodulating agent Substances 0.000 claims description 14
- 229940121354 immunomodulator Drugs 0.000 claims description 14
- 230000002584 immunomodulator Effects 0.000 claims description 14
- 241000701161 unidentified adenovirus Species 0.000 claims description 9
- 241000700605 Viruses Species 0.000 claims description 8
- 208000019420 lymphoid neoplasm Diseases 0.000 claims description 8
- 108700005077 Viral Genes Proteins 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 230000010076 replication Effects 0.000 claims description 7
- 210000004881 tumor cell Anatomy 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 229940124622 immune-modulator drug Drugs 0.000 claims description 6
- 239000013603 viral vector Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 230000003308 immunostimulating effect Effects 0.000 claims description 4
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims description 3
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 3
- 102100036846 C-C motif chemokine 21 Human genes 0.000 claims description 3
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 claims description 3
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 3
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 3
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 3
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 3
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 3
- 229960001438 immunostimulant agent Drugs 0.000 claims description 3
- 239000003022 immunostimulating agent Substances 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 102100036842 C-C motif chemokine 19 Human genes 0.000 claims description 2
- 102100025277 C-X-C motif chemokine 13 Human genes 0.000 claims description 2
- -1 CCL4 Proteins 0.000 claims description 2
- 102100038078 CD276 antigen Human genes 0.000 claims description 2
- 101710185679 CD276 antigen Proteins 0.000 claims description 2
- 101150013553 CD40 gene Proteins 0.000 claims description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 2
- 108091026890 Coding region Proteins 0.000 claims description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 2
- 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 claims description 2
- 101000858064 Homo sapiens C-X-C motif chemokine 13 Proteins 0.000 claims description 2
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 claims description 2
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 2
- 101001082073 Homo sapiens Interferon-induced helicase C domain-containing protein 1 Proteins 0.000 claims description 2
- 101000864662 Homo sapiens Probable ATP-dependent RNA helicase DHX58 Proteins 0.000 claims description 2
- 101000763579 Homo sapiens Toll-like receptor 1 Proteins 0.000 claims description 2
- 101000763537 Homo sapiens Toll-like receptor 10 Proteins 0.000 claims description 2
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 claims description 2
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 claims description 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims description 2
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 claims description 2
- 101000669406 Homo sapiens Toll-like receptor 6 Proteins 0.000 claims description 2
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims description 2
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 claims description 2
- 101000904152 Homo sapiens Transcription factor E2F1 Proteins 0.000 claims description 2
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 2
- 102100027353 Interferon-induced helicase C domain-containing protein 1 Human genes 0.000 claims description 2
- 102000014150 Interferons Human genes 0.000 claims description 2
- 108010050904 Interferons Proteins 0.000 claims description 2
- 102000013462 Interleukin-12 Human genes 0.000 claims description 2
- 108010065805 Interleukin-12 Proteins 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 102000000588 Interleukin-2 Human genes 0.000 claims description 2
- 102000002698 KIR Receptors Human genes 0.000 claims description 2
- 108010043610 KIR Receptors Proteins 0.000 claims description 2
- 102000017578 LAG3 Human genes 0.000 claims description 2
- 101150030213 Lag3 gene Proteins 0.000 claims description 2
- 102100030090 Probable ATP-dependent RNA helicase DHX58 Human genes 0.000 claims description 2
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims description 2
- 102100027010 Toll-like receptor 1 Human genes 0.000 claims description 2
- 102100027009 Toll-like receptor 10 Human genes 0.000 claims description 2
- 102100024333 Toll-like receptor 2 Human genes 0.000 claims description 2
- 102100024324 Toll-like receptor 3 Human genes 0.000 claims description 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims description 2
- 102100039357 Toll-like receptor 5 Human genes 0.000 claims description 2
- 102100039387 Toll-like receptor 6 Human genes 0.000 claims description 2
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims description 2
- 102100033110 Toll-like receptor 8 Human genes 0.000 claims description 2
- 102100033117 Toll-like receptor 9 Human genes 0.000 claims description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims description 2
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims description 2
- 239000012190 activator Substances 0.000 claims description 2
- 102000046157 human CSF2 Human genes 0.000 claims description 2
- 102000050313 human E2F1 Human genes 0.000 claims description 2
- 229940126546 immune checkpoint molecule Drugs 0.000 claims description 2
- 229940079322 interferon Drugs 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 230000000174 oncolytic effect Effects 0.000 claims description 2
- 238000007910 systemic administration Methods 0.000 claims description 2
- 230000026683 transduction Effects 0.000 claims description 2
- 238000010361 transduction Methods 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 230000002519 immonomodulatory effect Effects 0.000 claims 2
- 238000002203 pretreatment Methods 0.000 claims 1
- 239000000090 biomarker Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 102100035473 2'-5'-oligoadenylate synthase-like protein Human genes 0.000 description 1
- 241000711404 Avian avulavirus 1 Species 0.000 description 1
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 102100034871 C-C motif chemokine 8 Human genes 0.000 description 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 1
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 description 1
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 1
- 102100035793 CD83 antigen Human genes 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 102100031150 Growth arrest and DNA damage-inducible protein GADD45 alpha Human genes 0.000 description 1
- 102100035688 Guanylate-binding protein 1 Human genes 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 101000597360 Homo sapiens 2'-5'-oligoadenylate synthase-like protein Proteins 0.000 description 1
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 1
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 1
- 101000946794 Homo sapiens C-C motif chemokine 8 Proteins 0.000 description 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 1
- 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 description 1
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
- 101001066158 Homo sapiens Growth arrest and DNA damage-inducible protein GADD45 alpha Proteins 0.000 description 1
- 101001001336 Homo sapiens Guanylate-binding protein 1 Proteins 0.000 description 1
- 101000604998 Homo sapiens Lysosome-associated membrane glycoprotein 3 Proteins 0.000 description 1
- 101001014059 Homo sapiens Metallothionein-2 Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 101000843562 Homo sapiens Transcription factor HES-4 Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 102100038213 Lysosome-associated membrane glycoprotein 3 Human genes 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 102100031347 Metallothionein-2 Human genes 0.000 description 1
- 108091033773 MiR-155 Proteins 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 241000837158 Senecavirus A Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 102100032891 Superoxide dismutase [Mn], mitochondrial Human genes 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 101710138750 Transcription factor E2F1 Proteins 0.000 description 1
- 102100030774 Transcription factor HES-4 Human genes 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 108010045815 superoxide dismutase 2 Proteins 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021148497A JP7455399B2 (ja) | 2016-03-10 | 2021-09-13 | 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法 |
| JP2023033622A JP2023060184A (ja) | 2016-03-10 | 2023-03-06 | 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法 |
| JP2025064594A JP2025100670A (ja) | 2016-03-10 | 2025-04-09 | 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662306470P | 2016-03-10 | 2016-03-10 | |
| US62/306,470 | 2016-03-10 | ||
| PCT/US2017/021694 WO2017156349A1 (en) | 2016-03-10 | 2017-03-09 | Methods of treating solid or lymphatic tumors by combination therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021148497A Division JP7455399B2 (ja) | 2016-03-10 | 2021-09-13 | 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019507761A JP2019507761A (ja) | 2019-03-22 |
| JP2019507761A5 true JP2019507761A5 (enExample) | 2020-04-16 |
| JP7208492B2 JP7208492B2 (ja) | 2023-01-19 |
Family
ID=59789875
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018545432A Active JP7208492B2 (ja) | 2016-03-10 | 2017-03-09 | 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法 |
| JP2021148497A Active JP7455399B2 (ja) | 2016-03-10 | 2021-09-13 | 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法 |
| JP2023033622A Pending JP2023060184A (ja) | 2016-03-10 | 2023-03-06 | 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法 |
| JP2025064594A Pending JP2025100670A (ja) | 2016-03-10 | 2025-04-09 | 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021148497A Active JP7455399B2 (ja) | 2016-03-10 | 2021-09-13 | 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法 |
| JP2023033622A Pending JP2023060184A (ja) | 2016-03-10 | 2023-03-06 | 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法 |
| JP2025064594A Pending JP2025100670A (ja) | 2016-03-10 | 2025-04-09 | 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US11497781B2 (enExample) |
| EP (1) | EP3426271B1 (enExample) |
| JP (4) | JP7208492B2 (enExample) |
| CN (1) | CN108778301A (enExample) |
| ES (1) | ES3041500T3 (enExample) |
| PL (1) | PL3426271T3 (enExample) |
| WO (1) | WO2017156349A1 (enExample) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| KR102089121B1 (ko) | 2013-03-14 | 2020-03-13 | 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 종양살상형 아데노바이러스 조성물 |
| EP3092049A1 (en) | 2014-01-08 | 2016-11-16 | Flodesign Sonics Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| WO2016144564A2 (en) | 2015-02-25 | 2016-09-15 | Memorial Sloan-Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| EP3283088A4 (en) | 2015-04-17 | 2018-10-24 | Memorial Sloan-Kettering Cancer Center | Use of mva or mvadeltae3l as immunotherapeutic agents against solid tumors |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| EP3291679B1 (en) | 2015-05-06 | 2021-12-15 | SNIPR Technologies Limited | Altering microbial populations & modifying microbiota |
| RS60792B1 (sr) | 2015-05-29 | 2020-10-30 | Agenus Inc | Anti-ctla-4 antitela i postupci za njihovu primenu |
| JP6954648B2 (ja) * | 2015-10-19 | 2021-10-27 | シージー オンコロジー， インコーポレイテッド | 併用療法による固形腫瘍又はリンパ系腫瘍の治療方法 |
| AU2016362495B2 (en) | 2015-12-02 | 2021-12-09 | Memorial Sloan-Kettering Cancer Center | Seneca valley virus (SVV) cellular receptor targeted oncotherapy |
| AU2017212713B2 (en) | 2016-01-27 | 2023-01-19 | Oncorus, Inc. | Oncolytic viral vectors and uses thereof |
| CA3013637A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| KR20180112024A (ko) | 2016-02-23 | 2018-10-11 | 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현 |
| EP3419662A4 (en) | 2016-02-25 | 2019-09-18 | Memorial Sloan Kettering Cancer Center | HUMAN FLT3L EXPRESSIVE RECOMBINANT MVA OR MVADELE3L AND USE THEREOF AS IMMUNOTHERAPEUTICS AGAINST SOLID TUMORS |
| CA3015650A1 (en) | 2016-02-25 | 2017-08-31 | Memorial Sloan Kettering Cancer Center | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy |
| EP3426271B1 (en) | 2016-03-10 | 2025-08-27 | CG Oncology, Inc. | Methods of treating solid tumors by combination therapy |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| GB201609811D0 (en) | 2016-06-05 | 2016-07-20 | Snipr Technologies Ltd | Methods, cells, systems, arrays, RNA and kits |
| RU2021127872A (ru) | 2016-06-30 | 2021-11-09 | Онкорус, Инк. | Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов |
| TWI843168B (zh) | 2016-10-11 | 2024-05-21 | 美商艾吉納斯公司 | 抗ｌａｇ－３抗體及其使用方法 |
| MD3551660T2 (ro) | 2016-12-07 | 2024-03-31 | Agenus Inc | Anticorpi anti-CTLA-4 și procedee de utilizare a acestora |
| AU2017375633C1 (en) | 2016-12-12 | 2023-04-27 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| CA3056392A1 (en) * | 2017-03-15 | 2018-09-20 | Amgen Inc. | Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer |
| AU2018251987B2 (en) * | 2017-04-14 | 2024-11-28 | Cg Oncology, Inc. | Methods of treating bladder cancer |
| EA201992575A1 (ru) | 2017-04-28 | 2020-04-13 | Мерк Шарп И Доум Корп. | Биомаркеры для терапии рака |
| EP3621646A4 (en) | 2017-05-12 | 2021-06-02 | Memorial Sloan Kettering Cancer Center | USEFUL VACCINE VIRUS MUTANTS FOR ANTI-CANCER IMMUNOTHERAPY |
| RU2771110C2 (ru) | 2017-07-26 | 2022-04-26 | Онкорус, Инк. | Онколитические вирусные векторы и их применение |
| SG11202002123XA (en) * | 2017-10-27 | 2020-04-29 | Merck Sharp & Dohme | Compositions and methods for treating liver cancer |
| JP2021507561A (ja) | 2017-12-14 | 2021-02-22 | フロデザイン ソニックス， インク．Ｆｌｏｄｅｓｉｇｎ Ｓｏｎｉｃｓ， Ｉｎｃ． | 音響トランスデューサドライバ及びコントローラ |
| EP3731850A4 (en) | 2017-12-29 | 2021-12-01 | Oncorus, Inc. | ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES |
| US10760075B2 (en) | 2018-04-30 | 2020-09-01 | Snipr Biome Aps | Treating and preventing microbial infections |
| JP7550449B2 (ja) * | 2018-04-02 | 2024-09-13 | デューク ユニバーシティ | ネオアジュバントがん治療 |
| AU2019251356B2 (en) | 2018-04-09 | 2025-06-12 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions with enhanced replication properties |
| US11564980B2 (en) | 2018-04-23 | 2023-01-31 | Nantcell, Inc. | Tumor treatment method with an individualized peptide vaccine |
| TWI787500B (zh) | 2018-04-23 | 2022-12-21 | 美商南特細胞公司 | 新抗原表位疫苗及免疫刺激組合物及方法 |
| AU2019301699C1 (en) | 2018-07-11 | 2024-10-10 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| CN110819657B (zh) * | 2018-08-10 | 2021-11-19 | 睿丰康生物医药科技(浙江)有限公司 | 一种减毒棒状病毒的制备方法及应用 |
| BR112021004692A2 (pt) | 2018-09-15 | 2021-06-08 | Memorial Sloan Kettering Cancer Center | poxvírus recombinantes para imunoterapia de câncer |
| TWI690597B (zh) * | 2018-11-14 | 2020-04-11 | 國立中央大學 | 泌尿上皮癌的檢測套組及檢測方法 |
| TWI894135B (zh) * | 2019-01-25 | 2025-08-21 | 德商百靈佳殷格翰國際股份有限公司 | 編碼ccl21之重組棒狀病毒 |
| US12024709B2 (en) | 2019-02-27 | 2024-07-02 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
| AU2020229875B2 (en) * | 2019-02-27 | 2025-01-16 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
| WO2021041518A2 (en) * | 2019-08-27 | 2021-03-04 | Turnstone Biologics Corp. | Methods for inducing an immune response against neoantigens |
| AU2020382614B2 (en) | 2019-11-12 | 2025-12-11 | Actym Therapeutics, Inc. | Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products |
| US20230241141A1 (en) * | 2020-05-20 | 2023-08-03 | Virocure, Inc. | Pharmaceutical composition for preventing or treating cancer |
| AU2021324883A1 (en) | 2020-08-12 | 2023-03-23 | Actym Therapeutics, Inc. | Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms |
| WO2022040365A1 (en) * | 2020-08-18 | 2022-02-24 | Curators Of The University Of Missouri | Compositions and methods of treatment comprising tumor-targeting bacteria and chemotherapy or immunotherapy agent |
| JP2023553010A (ja) | 2020-12-03 | 2023-12-20 | バテル・メモリアル・インスティテュート | 非ウイルス性送達のためのポリマーナノ粒子およびｄｎａナノ構造組成物ならびに方法 |
| CN114681612B (zh) * | 2020-12-30 | 2024-10-25 | 苏州百迈生物医药有限公司 | 一种膀胱灌注药物及其制备方法和应用 |
| JP2024516108A (ja) | 2021-04-07 | 2024-04-12 | バテル・メモリアル・インスティテュート | 非ウイルス性担体を同定および使用するための迅速な設計、構築、試験、および学習技術 |
| CA3235418A1 (en) | 2021-11-09 | 2023-05-19 | Actym Therapeutics, Inc. | Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment |
| EP4466000A2 (en) * | 2022-01-19 | 2024-11-27 | Istari Oncology, Inc. | Oncolytic virus regimens for the treatment of cancer |
| GB202209518D0 (en) | 2022-06-29 | 2022-08-10 | Snipr Biome Aps | Treating & preventing E coli infections |
| WO2024054293A1 (en) * | 2022-09-08 | 2024-03-14 | Research Institute At Nationwide Children's Hospital | Oncolytic virus combination to maximize oncolytic activity |
| EP4583897A1 (en) * | 2022-09-08 | 2025-07-16 | Seneca Therapeutics, Inc. | Cancer therapies with oncolytic virus and an immune checkpoint inhibitor |
| AU2023398796A1 (en) * | 2022-12-15 | 2025-06-26 | Kalivir Immunotherapeutics, Inc. | Compositions of cd47/sirp-alpha immune checkpoint inhibitors and uses thereof |
| WO2025072751A1 (en) | 2023-09-29 | 2025-04-03 | Battelle Memorial Institute | Polymer nanoparticle compositions for in vivo expression of polypeptides |
| WO2025122954A1 (en) | 2023-12-08 | 2025-06-12 | Battelle Memorial Institute | Use of dna origami nanostructures for molecular information based data storage systems |
| WO2025251009A1 (en) * | 2024-05-31 | 2025-12-04 | Cg Oncology, Inc. | Methods of treating bladder cancer using an oncolytic virus and a transduction-enhancing agent |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7250A (en) | 1850-04-02 | Improved surface-condenser for steam-engines | ||
| US297A (en) | 1837-07-29 | Improvement in fire-arms | ||
| US4590071A (en) | 1984-09-25 | 1986-05-20 | Xoma Corporation | Human melanoma specific immunotoxins |
| US5182368A (en) | 1986-06-13 | 1993-01-26 | Ledbetter Jeffrey A | Ligands and methods for augmenting B-cell proliferation |
| US5247069A (en) | 1986-06-13 | 1993-09-21 | Oncogen | Ligands and methods for augmenting B-cell proliferation |
| SE8701004D0 (sv) | 1987-03-11 | 1987-03-11 | Astra Ab | Method for therapy of leukemias and certain other malignancies |
| FR2656800B1 (fr) | 1990-01-08 | 1992-05-15 | Roussy Inst Gustave | Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques. |
| US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
| US5874082A (en) | 1992-07-09 | 1999-02-23 | Chiron Corporation | Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation |
| AU5098493A (en) | 1992-08-21 | 1994-03-15 | Schering Corporation | Cd40 ligand, anti cd40 antibodies, and soluble cd40 |
| DE69433406T2 (de) | 1993-10-01 | 2004-10-07 | Immunex Corp | Antikörper gegen cd40 |
| ATE267607T1 (de) | 1993-12-23 | 2004-06-15 | Immunex Corp | Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten |
| JPH07291996A (ja) | 1994-03-01 | 1995-11-07 | Yuu Honshiyo | ヒトにおけるプログラムされた細胞死に関連したポリペプチド、それをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞、そのポリペプチドの抗体、およびそのポリペプチドまたはその抗体を含有する薬学的組成物 |
| US7001764B2 (en) | 1995-06-27 | 2006-02-21 | Cell Genesys, Inc. | Compositions comprising tissue specific adenoviral vectors |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6432700B1 (en) | 1997-03-03 | 2002-08-13 | Cell Genesys, Inc. | Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same |
| AU744725B2 (en) | 1997-03-03 | 2002-02-28 | Cold Genesys, Inc. | Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same |
| US6051228A (en) | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
| AU2003252891B2 (en) | 1998-09-10 | 2006-06-01 | Cold Genesys, Inc. | Adenovirus vectors containing cell status-specific response elements and methods of use thereof |
| US6900049B2 (en) | 1998-09-10 | 2005-05-31 | Cell Genesys, Inc. | Adenovirus vectors containing cell status-specific response elements and methods of use thereof |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| US6495130B1 (en) | 1998-12-30 | 2002-12-17 | Calydon, Inc. | Target cell-specific adenoviral vectors containing E3 and methods of use thereof |
| US20080213778A1 (en) | 1998-12-30 | 2008-09-04 | Millennium Pharmaceuticals, Inc. | Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses |
| US7041474B2 (en) | 1998-12-30 | 2006-05-09 | Millennium Pharmaceuticals, Inc. | Nucleic acid encoding human tango 509 |
| US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
| PT1210428E (pt) | 1999-08-23 | 2015-07-21 | Genetics Inst Llc | Pd-1, um recetor para b7-4 e suas utilizações |
| ES2282133T3 (es) | 1999-08-24 | 2007-10-16 | Medarex, Inc. | Anticuerpos frente a la ctla-4 humano y sus usos. |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| CA3016482A1 (en) | 1999-11-30 | 2001-06-07 | Mayo Foundation For Medical Education And Research | B7-h1, a novel immunoregulatory molecule |
| US6687360B2 (en) | 1999-12-30 | 2004-02-03 | At&T Corp. | Personal IP follow-me service |
| AU2001236621B2 (en) | 2000-02-01 | 2006-06-15 | Mycenax Biotech Inc. | Cd40-binding apc-activating molecules |
| US7048920B2 (en) | 2000-03-24 | 2006-05-23 | Cell Genesys, Inc. | Recombinant oncolytic adenovirus for human melanoma |
| US6692736B2 (en) | 2000-03-24 | 2004-02-17 | Cell Genesys, Inc. | Cell-specific adenovirus vectors comprising an internal ribosome entry site |
| WO2001073093A2 (en) | 2000-03-24 | 2001-10-04 | Cell Genesys, Inc. | Cell-specific adenovirus vectors comprising an internal ribosome entry site |
| US7063845B2 (en) | 2000-04-28 | 2006-06-20 | Gemini Science, Inc. | Human anti-CD40 antibodies |
| US20030059427A1 (en) | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
| NZ522844A (en) | 2000-06-28 | 2005-02-25 | Brigham & Womens Hospital | PD-L2 molecules: novel PD-1 ligands and methods to identify compounds to modulate T cell activation |
| AR036993A1 (es) | 2001-04-02 | 2004-10-20 | Wyeth Corp | Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas |
| US7794710B2 (en) | 2001-04-20 | 2010-09-14 | Mayo Foundation For Medical Education And Research | Methods of enhancing T cell responsiveness |
| ATE374214T1 (de) | 2001-04-27 | 2007-10-15 | Kirin Brewery | Monoklonaler anti-cd-40-antikörper |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| CA2466279A1 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| WO2003086459A1 (en) | 2002-04-12 | 2003-10-23 | Medarex, Inc. | Methods of treatement using ctla-4 antibodies |
| US7595048B2 (en) | 2002-07-03 | 2009-09-29 | Ono Pharmaceutical Co., Ltd. | Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1 |
| JP4511943B2 (ja) | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Ｐｄ−１に対する抗体およびその使用 |
| US7459154B2 (en) | 2002-12-26 | 2008-12-02 | Cell Genesys, Inc. | Methods and reagents for the enhancement of virus transduction in the bladder epithelium |
| MXPA05007019A (es) | 2002-12-30 | 2005-08-18 | Amgen Inc | Terapia de combinacion con factores co-estimuladores. |
| US20040197312A1 (en) | 2003-04-02 | 2004-10-07 | Marina Moskalenko | Cytokine-expressing cellular vaccine combinations |
| US20050282280A1 (en) | 2003-08-28 | 2005-12-22 | Ennist David L | Oncolytic adenoviral vectors encoding GM-CSF |
| US20050186178A1 (en) | 2003-08-28 | 2005-08-25 | Ennist David L. | Oncolytic adenoviral vectors encoding GM-CSF |
| WO2005030261A1 (en) | 2003-08-28 | 2005-04-07 | Cell Genesys, Inc. | Oncolytic adenoviral vectors encoding gm-csf |
| US20050136055A1 (en) | 2003-12-22 | 2005-06-23 | Pfizer Inc | CD40 antibody formulation and methods |
| US7473418B2 (en) | 2004-03-25 | 2009-01-06 | Cell Genesys, Inc. | Pan cancer oncolytic vectors and methods of use thereof |
| TW200607859A (en) | 2004-08-23 | 2006-03-01 | Cell Genesys Inc | Oncolytic adenoviral vectors encoding GM-CSF |
| US20060062764A1 (en) * | 2004-08-25 | 2006-03-23 | Seshidar-Reddy Police | Fiber-modified adenoviral vectors for enhanced transduction of tumor cells |
| JP5303146B2 (ja) | 2004-10-06 | 2013-10-02 | メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ | Ｂ７−ｈ１ならびに癌の診断、予後診断および処置の方法 |
| LT2650020T (lt) | 2005-05-06 | 2016-12-12 | Providence Health & Services - Oregon | Trimerinio ox40-immunoglobulino sulietas baltymas ir naudojimo būdai |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101888321B1 (ko) | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| GB0522476D0 (en) | 2005-11-03 | 2005-12-14 | Biovex Ltd | Oncolytic herpes virus vectors |
| US8557257B2 (en) | 2006-03-24 | 2013-10-15 | Oncovac Inc. | Mycobacterial immunotherapy for cancer treatment |
| JP6092497B2 (ja) | 2006-03-30 | 2017-03-08 | ユニバーシティー オブ カリフォルニア | 抗ｃｔｌａ−４抗体の限局性分泌のための方法および組成物 |
| US7919079B2 (en) | 2006-03-31 | 2011-04-05 | Biosante Pharmaceuticals, Inc. | Cancer immunotherapy compositions and methods of use |
| NZ596237A (en) | 2006-12-27 | 2012-07-27 | Dana Farber Cancer Inst Inc | Compositions and methods for the treatment of infections and tumors |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| WO2010027423A2 (en) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
| US8840881B2 (en) | 2008-08-28 | 2014-09-23 | Aduro Gvax Inc. | Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer |
| HUE030807T2 (en) | 2008-09-26 | 2017-05-29 | Dana Farber Cancer Inst Inc | Human anti-PD-1, anti-PD-L1 and anti-PD-L2 antibodies and their applications |
| TWI605828B (zh) | 2008-12-09 | 2017-11-21 | 建南德克公司 | 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途 |
| US9345787B2 (en) | 2008-12-22 | 2016-05-24 | Targovax Oy | Adenoviral vectors and methods and uses related thereto |
| WO2010072900A1 (en) | 2008-12-22 | 2010-07-01 | Oncos Therapeutics | Oncolytic adenoviral vectors and methods and uses related thereto |
| EP2517556B2 (en) | 2009-07-08 | 2023-03-22 | Kymab Limited | Site-Specific Recombination Method, Rodents & Rodent Cells capable of Expressing Chimaeric Antibodies or Chains |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| CN102892786B (zh) | 2010-03-11 | 2016-03-16 | Ucb医药有限公司 | Pd-1抗体 |
| CA2812093A1 (en) * | 2010-09-24 | 2012-03-29 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors coding for monoclonal anti - ctla - 4 antibodies |
| DK2646552T3 (en) | 2010-12-02 | 2017-10-23 | Pieris Pharmaceuticals Gmbh | MUTEINES OF HUMAN LIPOCALIN 2 WITH AFFINITY FOR CTLA-4 |
| EP3403672A1 (en) | 2011-04-20 | 2018-11-21 | Medlmmune, LLC | Antibodies and other molecules that bind b7-h1 and pd-1 |
| ES2709654T3 (es) | 2011-04-29 | 2019-04-17 | Apexigen Inc | Anticuerpos anti-CD40 y métodos de uso |
| US9056133B2 (en) | 2011-05-25 | 2015-06-16 | Cti-S.A. | Pharmaceutical kit and method for treating cancer |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| US10238698B2 (en) * | 2012-01-25 | 2019-03-26 | Dnatrix, Inc. | Biomarkers and combination therapies using oncolytic virus and immunomodulation |
| AR090263A1 (es) * | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| KR20150038066A (ko) | 2012-07-30 | 2015-04-08 | 알렉스 와 힌 영 | 종양 세포, 암세포파괴 바이러스 벡터 및 면역 체크포인트 조절인자를 갖는 암 백신 시스템 |
| CA2909432C (en) | 2013-04-18 | 2025-11-18 | Tilt Biotherapeutics Oy | Enhanced adoptive cell therapy |
| JP2016540505A (ja) | 2013-11-22 | 2016-12-28 | ディーエヌエートリックス インコーポレイテッド | アデノウイルス発現免疫細胞刺激受容体アゴニスト |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| JP6843736B2 (ja) * | 2014-07-16 | 2021-03-17 | トランジェーヌＴｒａｎｓｇｅｎｅ | 腫瘍溶解性ウイルスと免疫チェックポイントモジュレーターとの組合せ |
| EA201790834A1 (ru) * | 2014-10-14 | 2018-01-31 | Новартис Аг | Молекулы антител к pd-l1 и их применение |
| JP6847846B2 (ja) | 2015-03-12 | 2021-03-24 | セセン バイオ，インコーポレイテッド | Ｅｐｃａｍ陽性膀胱癌を標的とする投薬戦略 |
| JP6954648B2 (ja) | 2015-10-19 | 2021-10-27 | シージー オンコロジー， インコーポレイテッド | 併用療法による固形腫瘍又はリンパ系腫瘍の治療方法 |
| EP3426271B1 (en) | 2016-03-10 | 2025-08-27 | CG Oncology, Inc. | Methods of treating solid tumors by combination therapy |
| AU2018251987B2 (en) | 2017-04-14 | 2024-11-28 | Cg Oncology, Inc. | Methods of treating bladder cancer |
-
2017
- 2017-03-09 EP EP17764159.4A patent/EP3426271B1/en active Active
- 2017-03-09 ES ES17764159T patent/ES3041500T3/es active Active
- 2017-03-09 CN CN201780015149.9A patent/CN108778301A/zh active Pending
- 2017-03-09 JP JP2018545432A patent/JP7208492B2/ja active Active
- 2017-03-09 WO PCT/US2017/021694 patent/WO2017156349A1/en not_active Ceased
- 2017-03-09 PL PL17764159.4T patent/PL3426271T3/pl unknown
- 2017-03-09 US US16/083,709 patent/US11497781B2/en active Active
-
2021
- 2021-09-13 JP JP2021148497A patent/JP7455399B2/ja active Active
-
2022
- 2022-08-26 US US17/822,677 patent/US12090183B2/en active Active
-
2023
- 2023-03-06 JP JP2023033622A patent/JP2023060184A/ja active Pending
-
2025
- 2025-02-12 US US19/051,663 patent/US20250302897A1/en active Pending
- 2025-04-09 JP JP2025064594A patent/JP2025100670A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019507761A5 (enExample) | ||
| JP2018530624A5 (enExample) | ||
| Tian et al. | Engineering strategies to enhance oncolytic viruses in cancer immunotherapy | |
| JP7455399B2 (ja) | 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法 | |
| Wang et al. | mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications | |
| Schirrmacher | From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment | |
| Bartlett et al. | Oncolytic viruses as therapeutic cancer vaccines | |
| Yan et al. | Enhancing cancer therapy: the integration of oncolytic virus therapy with diverse treatments | |
| JP2020516590A5 (enExample) | ||
| US11596685B2 (en) | Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids | |
| JP2015523412A (ja) | 腫瘍細胞、ＧＭ‐ＣＳＦのトランスジェニック発現を伴う腫瘍溶解性ウイルスベクター、および免疫チェックポイントモジュレーターなどの成分の少なくとも２種または全３種の同時投与により作られる生のｉｎｖｉｖｏ腫瘍特異的がんワクチンシステム | |
| Malhotra et al. | Oncolytic viruses and cancer immunotherapy | |
| JP7239911B2 (ja) | 腫瘍溶解性ワクシニアウイルスおよびｎｋ細胞を含む治療剤、ならびに腫瘍および／またはがんの治療のための薬物のためのその使用 | |
| JP2011519869A5 (enExample) | ||
| Jiang et al. | mRNA vaccination in breast cancer: current progress and future direction | |
| CN119563028A (zh) | 具有分泌抗原和免疫调节物的合成自扩增mRNA分子 | |
| JP2020528890A (ja) | 腫瘍を治療するためのウイルス | |
| Chekaoui et al. | Cancer vaccines: an update on recent achievements and prospects for cancer therapy | |
| Li et al. | Oncolytic viruses in cancer immunotherapy | |
| JP2016501538A5 (enExample) | ||
| Liu et al. | Novel insight into the role of immunotherapy in gastrointestinal cancer | |
| JP2025049296A (ja) | 高度にコンパクトな多入力論理ゲートをコードする核酸ベクターを使用して疾患を処置する方法 | |
| Kloos et al. | Retargeted oncolytic viruses provoke tumor-directed T-cell responses | |
| Ejaz et al. | Therapeutic cancer vaccines; past, present, and future aspects | |
| Garcia-Aragoncillo et al. | Design of virotherapy for effective tumor treatment |